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Abstract
Background: Organic cation transporters (OCTs) in the renal proximal tubule are important for the excretion of
both exo- and endogenous compounds, and chronic kidney disease (CKD) alter the expression of OCT. Metformin
is a well-known substrate for OCT, and recently, we demonstrated that positron emission tomography (PET) with
11C-labelled metformin (11C-metformin) is a promising approach to evaluate the function of OCT. The aim of this
study is therefore to examine renal pharmacokinetics of 11C-metformin and expression of OCTs in a transgenic
(RenTGF-β1) mouse model of CKD.
Methods: Age- and sex-matched RenTGF-β1 (Tg) and wildtype (WT) mice were used (5–8/group). Animals received
an iv bolus of 11C-metformin followed by 90-min dynamic PET and MRI scan. PET data were analysed using a
one-tissue compartment model. Renal protein abundance of OCT2 (by Western blot) as well as OCT1, OCT2, and
MATE1 messenger RNA (mRNA) (by RT-PCR) was examined.
Results: Protein expression of the basolateral uptake transporter OCT2 was 1.5-fold lower in Tg mice compared to
WT mice while OCT1 and MATE1 mRNA expression did not differ between the two groups. The influx rate constant
of 11C-metformin in renal cortex (K1) was 2.2-fold lower in transgenic mice whereas the backflux rate constant (k2)
was similar in the two groups, consistent with protein expression. Total body clearance (TBC) correlated within each
group linearly with K1.
Conclusions: In conclusion, this study demonstrates that both renal OCT2 expression and 11C-metformin uptake
are reduced in CKD mice. This potentially makes 11C-metformin valuable as a PET probe to evaluate kidney
function.
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Background
The prevalence of chronic kidney disease (CKD) is dra-
matically increasing worldwide [1–5]. Renal accumulation
and abnormal regulation of extracellular matrix molecules
are both characteristics of CKD and can be directly linked
to impaired kidney function. Importantly, diabetic ne-
phropathy is the most frequent cause of end-stage renal
disease accounting for more than half of new diagnoses [6].
Both acute and chronic kidney failure are associated
with altered expression of numerous transport proteins
along the nephron including organic cation transporters
(OCTs) located to the proximal tubules [7, 8]. OCTs
are responsible for renal excretion of both exo- and en-
dogenous organic cations in the kidneys, and decreased
expression may lead to the accumulation of these com-
pounds to toxic levels [9, 10]. The anti-diabetic drug
metformin is a well-known substrate for OCTs, and
11C-labelled metformin (11C-metformin) was recently
demonstrated as a PET probe for the evaluation of
renal OCTs in rats and pigs [11]. In proximal tubule of
mice, OCT2 (and to a lesser degree OCT1) mediates
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basolateral uptake of metformin whereas the multidrug
and toxin extrusion protein 1 (MATE1) is responsible
for excretion into the tubule lumen in a H+-coupled
electroneutral manner [12, 13].
CKD can be studied in a mouse model with TGFβ-
induced chronic kidney disease (RenTGF-β1). These mice
express proximal tubular dysfunction, tubular basement
membrane thickening, interstitial fibrosis, and proteinuria
when they are approximately 4-month old [14, 15]. The
structural changes are mainly located to the basolateral
part of the cells along the nephron which could lead to
altered OCT2 function.
Presently, it is unknown whether 11C-metformin can be
used as a renal in vivo imaging tool to detect functional
abnormalities of OCTs in CKD. Therefore, the present
study was designed to investigate renal pharmacokinetics




For the kinetic modelling study, we used the previously
described RenTGF-β1 transgenic (Tg) mouse strain ex-
pressing mutated porcine TGF-β1 under control of the
Ren-1c promotor [16]. Tg females (n = 8) between 4- and
5-month old were used, and age- and sex-matched
wildtype (WT) littermates (n = 5) were used as control
animals. To further investigate the relative importance of
OCT1/2 and MATE1, we calculated total body clearance
(TBC) for animals used in [17]. This included controls at
baseline and after treatment with cimetidine (an OCT1/2
inhibitor) or pyrimethamine (a MATE1 inhibitor) and
OCT1/2 knock-out mice. All animals were housed at the
animal facility at the Aarhus University and handled
according to the guidelines and procedures approved by
the Animal Experiments Inspectorate, Denmark. Special
characteristics for the mice models have been published
previously [15, 18, 19].
mRNA expression by real-time RT-PCR, electrophoresis,
and immunoblotting analysis
From Tg and WT mice, messenger RNA (mRNA) was
extracted as previously described (n = 8/group) and
amounts of OCT1, OCT2, and MATE1 were measured
[14]. The primer pairs used in the study were murine
OCT1: forward 5′-CATCTTGTACCAGGTGGCCT-3′,
reverse 5′-CCGCCTGAGTGGTTCTCTTC-3′; murine
OCT2: forward 5′-AAATGGTCTGCCTGG TCAAC-3′,
reverse 5′-AGGCCAACCACAGCAAATAC-3′; murine
MATE1: forward 5′-CTGCTCTTCAGACAGGACCC-3′,
reverse 5′-TGACAAGGTTAG CTGCGATG-3′; and
GAPDH: forward 5′-ATGTTCCAGTATGACTCCACT
CACG-3′, reverse 5′-GAAGA CACCAGTAGACTCCA
CGACA-3′. Proteins from renal tissue (n = 7/group)
were analysed with Western blotting as previously de-
scribed [20] with OCT2 rabbit polyclonal antibody (1:500,
LS-C80615, LifeSpan Bioscience, Seattle, WA, USA).
11C synthesis and microPET/MR
11C-metformin was prepared as previously described
[11]. Dynamic PET- and anatomical MR-imaging were
conducted in Tg (n = 8) and WT (n = 5) mice using
Mediso nanoScan PET/MR (Mediso Ltd., Hungary). An-
aesthesia was induced in a chamber filled with 4–5 %/
0.5 % isoflurane/oxygen inhalation mixture. A catheter
was placed into the tail vein, and sterile saline (~0.2 mL)
was administered to insure adequate hydration. A single
bolus of 11C-metformin (7.7 ± 4.0 MBq/mouse) was
injected via the catheter followed by 90-min dynamic
PET- and anatomical MR-imaging. Body temperature
was kept at 36–37 °C throughout the intervention, and
respiration frequency was monitored. Dynamic PET
data were reconstructed as previously reported [17].
PET image analysis
Multiple regions of interest (ROIs) were placed on the
renal cortex, heart, and liver using PMOD version 3.5
(PMOD Technologies Ltd, Zurich, Switzerland) creating
a volume of interest (VOI). Half-moon shaped renal cor-
tex VOIs were defined on an average image of the 33
PET frames. Subsequently, it was verified that the VOIs
were placed within the renal cortex in each frame. Hep-
atic VOIs were drawn on the first 25 frames where it
can easily be identified and averaged. The heart was used
as an image-derived input function. Frames from the
first 20 s were averaged and ROI circles with a diameter
of 15 pixels were placed on the six most intensive slices
in the middle of the heart. Correct positioning of the
liver and heart VOIs were checked in each time frame
and adjusted if needed. Time-activity curves (TACs)
were generated from the VOIs.
Kinetic modelling
Dynamic PET data for each kidney cortex were fitted
using a one-tissue compartment model with two pa-
rameters: K1, the influx rate constant (from blood into
the tissue compartment) and k2, the backflux rate
constant (out of the tissue compartment). The kinetic
parameters were estimated by minimizing the residual
sum of squares (RSS) using the Levenberg-Marquard
algorithm. A single mouse was excluded from the ana-
lyses because the model fit yielded non-physiological
parameter estimates.
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TBC during 90 min was calculated based on the imaged-
derived input function from the following equation:
TBC ¼ ID
AUC 0−90 minð Þ
where ID is injected dose relative to kilogram body weight
and AUC(0–90 min) represents Area Under the Curve of
the image-derived input function up to 90 min.
Statistics
All data are presented as mean ± standard error of mean
(SEM), and the statistical analyses were performed using
Sigma Plot version 11.0. The Kolmogorov-Smirnov test
with Lillefors’ correction was used to test all data for
normality, and the unpaired data were compared using
Student’s t test. Data that were not normally distributed
were compared using the Mann-Whitney rank sum test.
Differences between groups were considered significant
when P < 0.05.
Results
Reduced mRNA and protein expression of renal OCT2 in
Tg mice
The mRNA expression of different relevant transport
proteins was investigated in total kidney tissue from a
different group of WT and Tg mice (n = 8/group). The
expression of OCT1 was not significantly different be-
tween WT and Tg mice (Fig. 1a); however, OCT2 mRNA
was 1.4-fold lower in Tg versus WT mice (P = 0.015,
Fig. 1b). MATE1 expression did not differ significantly
between WT and Tg mice (Fig. 1c). Protein levels of
OCT2 were 1.5-fold lower in Tg mice when investigated
with Western blotting in membrane fraction of kidney
tissue (n = 7/group, P = 0.026, Fig. 1d, e).
Rapid renal clearance of 11C-metformin visualised by PET
After 90-min dynamic PET-imaging, the highest amount
of radioactivity was found in the urinary bladder. The
renal distribution of 11C-metformin peaked from 1–5 min


















Fig. 1 Expression of OCT2 is reduced in CKD mice. a–c Whole kidney tissue expression of a OCT1 mRNA, b OCT2 mRNA, and c MATE1 mRNA
(values are mean ± SEM, n = 8) (*P = 0.015). d–e Western blot for OCT2 protein (d) with a wildtype mouse as positive control (lane 1) and a OCT1/2
KO mouse as negative control (lane 2). The band (arrow) corresponding to the positive control in the Tg and WT mice is assumed to represent OCT2
protein abundance (e) (values are relative to total protein and represent mean ± SEM, n = 7) (*P = 0.026)
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PET/MR image due to extensive urinary excretion
(Fig. 2). Time-activity curves for WT and Tg mice were
generated (Fig. 3). Of note is the absence of pro-
nounced visual differences in 11C-metformin kinetics
between WT and Tg mice during the first 30 min.
Impaired total body clearance of 11C-metformin correlates
with decreased uptake in renal cortex of Tg mice
TBC of 11C-metformin was determined using the image-
derived input function and was 1.8-fold lower in Tg
compared to WT mice (P = 0.010, Fig. 4a and Table 1).
No difference was observed between the left and right
kidney; consequently, rate constants were expressed as
means of both kidneys. The influx rate constant in renal
cortex (K1) was 2.2-fold lower in Tg mice (P = 0.027,
Fig. 4b). k2 did not differ significantly between the two
groups (P = 0.11, data not shown). TBC correlated
within each group with K1 (R = 0.79 WT, R = 0.91 Tg,
Fig. 4c). Logan plot of 11C-metformin from 20–90 min
showed that the liver volume of distribution did not differ
significantly between the two groups (data not shown).
OCT1/2 status is crucial for 11C-metformin TBC
Ablation of OCT1/2 or pre-treatment with cimetidine
had a profound lowering effect on TBC whereas inhi-
bition of MATE1 by pyrimethamine slightly increased
TBC albeit insignificantly (Table 1).
Discussion
Here we provide data from dynamic PET-imaging with
11C-metformin in a well-established mouse model of
CKD. For the first time, we demonstrate that influx rate
constant of 11C-metformin into the renal cortex is lower
in a state of chronic kidney disease. Furthermore, ex-
pression of the basolateral uptake transporter OCT2 is
lower in the transgenic mouse model. This finding may
have implications for developing radiolabelled metfor-
min PET-imaging as a method to evaluate kidney func-
tion changes.
In Tg mice, the structural changes and associated
changes in the biochemical environment are mainly lo-
cated to the basolateral part of the epithelial cells along
the nephron. This is consistent with the observations
that OCT2 mRNA expression levels in Tg mice are re-
duced compared with WT mice whereas there are no
difference in the mRNA expression of the apical MATE1
transporter. The absence of changes in OCT1 mRNA
level is consistent with previous findings in a rat model
of chronic kidney failure [7]. To confirm the importance
of the mRNA findings, we investigated protein levels of
OCT2 and found a comparable reduction in the OCT2
protein expression in Tg mice. This could suggest that
OCT2 expression is more sensitive to renal damage
than OCT1.
Metformin is described to be a superior substrate for
OCT2 than OCT1, and the capacity to transport metfor-
min is 10–100-fold greater for OCT2 when compared to
OCT1 [21]. This would make metformin excretion more
sensitive to alterations in OCT2- rather than OCT1 ex-
pression, and thus, 11C-metformin PET is potentially an
in vivo imaging probe for OCT2 evaluation.
Renal excretion of metformin in the proximal tubule
accounts for approximately 80 % of renal clearance of
the drug under normal conditions [12, 13, 22]. In mice,
OCT1 and -2 are responsible for basolateral uptake of
metformin and TBC was reported to be 4.5-fold lower
Fig. 2 Coronal whole body PET with 11C-metformin merged with T1-weighted MRI-sequence in a WT mouse (upper panel) and a Tg mouse
(lower panel). The projection is posterior to the liver and heart. Radioactivity in the kidneys peaks from 1 to 5 min and decreases towards
90 min because of extensive urinary excretion. Scale bar to the left represents standard uptake value (SUV) 0–5
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in OCT1/2 knock-out mice [12]. In the present study,
we found that TBC of 11C-metformin was 1.8-fold lower
in Tg mice than WT mice and still lower after blockade
or removal of OCT1/2. Thus, these findings suggest a
lower expression of OCT2 in Tg mice to be responsible
for the reduced TBC of 11C-metformin. In support of
this view, the pharmacokinetic analyses of 11C-metfor-
min in renal cortex revealed a lower K1 in Tg mice, i.e.,
the basolateral cellular uptake in renal cortex is slower
as there is lower expression level of the basolateral uptake
transporter. Besides the transporter mediated cellular
uptake in renal cortical compartment, GFR and renal
blood flow also influence K1. GFR is reported to be
approximately twofold lower in 3-month-old Tg mice
determined by 51Cr-EDTA [15], but as glomerular
filtration only accounts for ~20 % of renal metformin
clearance, this cannot solely explain the observed dif-
ference in K1.
MATE1 is mainly responsible for the excretion of
metformin into proximal tubule lumen, and TBC of
metformin has been shown to be approximately fourfold
lower in MATE1−/− mice [13]. Interestingly, the bloc-
kade of MATE1 by pre-treatment with pyrimethamine
did not lower TBC of 11C-metformin perhaps reflecting
higher kidney versus liver abundance of MATE1. We
found no difference in backflux rate constant (k2) of
11C-metformin between the two groups consistent with
comparable MATE1 expression levels. Overall, OCT2
seems to be responsible for a lower 11C-metformin up-
take in the renal cortex in our mouse model for CKD.
In clinical practice, metformin treatment is only rec-
ommended for individuals without CKD or mild-to-
moderate stages of CKD due to the risk of lactic aci-
dosis, which is a rare but potentially life-threatening
complication [23, 24]. With no clear-cut correlation
between plasma levels of metformin and prevalence of
lactic acidosis, the literature is currently conflicting
about the safety of the drug and national restrictions
are excluding a number of patients from the beneficial
effects of metformin. Here we present a new approach
to understand the mechanisms by which metformin is
handled by the kidneys in stages of CKD. This approach
A B
Fig. 3 Time-activity curves of 11C-metformin in the image-derived input function (a) and in the kidneys (b) in Tg and WT mice. Data are
expressed as standard uptake value (SUV) = concentration [kBq/mL] × (body weight [g]/injected dose [kBq]). The data represent means + SEM.
Closed circles =WT; Open circles = Tg
A B C
Fig. 4 Kinetic analysis of dynamic PET data. a TBC of 11C-metformin in WT (n = 5) and Tg (n = 8) mice determined from image-derived input
function. b K1 in renal cortex determined from compartmental analysis. c Correlation between K1 and TBC (*P < 0.05). Closed circles =WT;
Open circles = Tg
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could form the basis of future clinical studies and ulti-
mately differentiate between patients with CKD who will
tolerate metformin treatment and who will not.
Possible limitations of this study relates to quantifi-
cation in small-animal PET. TBC and kinetic modelling
were based on the image-based input function from the
heart rather than an input function measured by blood
sampling. Fast and repeated blood sampling from mice
is troublesome partly because of the non-triviality of
obtaining a proper arterial line and partly because of the
limited amount of blood that can be safely taken. The
heart region is assumed to be proportional to plasma
concentration of 11C-metformin due to negligible uptake
into erythrocytes during the scan period (Lars Chr.
Gormsen, submitted). However, this proportionality can
be affected by the size of the heart and haematocrit. The
heart size tends to be smaller in Tg mice when evaluated
on PET images. This would include more cardiac tissue
with minimal 11C-metformin uptake in the region and
thereby dilute the concentration of 11C-metformin in Tg
mice. Haematocrit is also lower in Tg mice [18] but
would account for the opposite effect because of negli-
gible uptake of 11C-metformin into erythrocytes. The
one-tissue compartment model used in the present
study produced the best fit which is consistent with
findings in pigs [11]. Even so, a more advanced kinetic
model might enable the discrimination of some of the
different components (blood flow, GFR, OCT-mediated
transport, and urine flow) in renal handling of 11C-met-
formin; however, we are not able to implement such an
approach on the current animal data because of limited
spatial resolution inherent in small-animal microPET
studies. We anticipate that some of these aspects are
manageable or even non-existent in future human scans.
Conclusions
It has previously been shown that OCT expression is af-
fected by CKD. In this study, we show that diminished
OCT2 expression in a mouse model of CDK reduced the
renal uptake of 11C-metformin and that TBC of 11C-met-
formin is lowered profoundly after ablation of OCT1/2 or
pre-treatment with cimetidine. Thus, 11C-metformin PET
warrants further investigation to assess OCT expression
and renal function in vivo.
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